As clinical trial protocols become increasingly complex, research sites face growing operational demands—from navigating intricate eligibility criteria and visit schedules to managing protocol amendments and documentation requirements. For biotech sponsors, these challenges can contribute to protocol deviations, increased costs, and delays in trial execution.

Could Digital Twins Offer a Smarter Way Forward?

By transforming complex protocols into structured, actionable guidance, protocol and patient digital twins have the potential to help clinical research teams anticipate risks, streamline workflows, and improve trial execution while allowing site staff to focus more time on patient care.

The industry's transition toward digital, machine-readable protocols is helping lay the foundation for these capabilities. The International Council for Harmonisation's (ICH) M11 guideline, which introduces the Clinical electronic Structured Harmonised Protocol (CeSHarP) template, supports greater consistency in how clinical trial protocols are structured and represented electronically.

This evolution comes at an important time. The WCG 2025 Clinical Research Site Challenges Report identifies trial complexity as a leading challenge for research sites, with administrative burden and complex protocol designs among the principal contributors.

Addressing these challenges requires more than adding another technology platform. It calls for more effective ways to translate protocol requirements into practical guidance that supports consistent execution, proactive risk management, and stronger collaboration between sponsors, CROs, and clinical sites.

At Novotech, we see the potential value of digital twins in helping sites apply complex protocol requirements to individual participant activities. Their usefulness will depend on the accuracy of the guidance, how well they fit existing workflows, and the clinical support available when questions arise.

Understanding Protocol and Patient Twins

Digital twins offer an emerging approach to managing the operational complexity of clinical trials. Two applications are particularly relevant: protocol twins and patient twins.

A protocol twin transforms a clinical trial protocol into a structured digital model that can help research teams interpret requirements, identify potential risks, and guide trial execution.

A patient twin applies protocol requirements to an individual participant's data and visit schedule, helping site teams identify required assessments, track progress, and recognize potential compliance risks.

The applications discussed here focus on supporting trial activities, rather than simulating disease progression or predicting treatment outcomes.

Together, these capabilities could help address some of the most persistent challenges facing clinical research sites:

  • Protocol complexity: Making eligibility criteria, procedures, endpoints, and visit schedules easier to interpret.
  • Administrative burden: Reducing time spent searching protocols, reviewing requirements, and identifying missing documentation.
  • Protocol amendments: Helping teams understand changes and their implications for ongoing trial activities.
  • Visit scheduling: Identifying narrow visit windows and potential scheduling conflicts before they result in deviations.
  • Quality oversight: Highlighting emerging risks and supporting more targeted monitoring and corrective actions.

For biotech sponsors, reducing these site-level challenges could also improve visibility into trial execution, support more efficient monitoring, and help protect study timelines and data quality.

Protocol Twins: Turning Complex Requirements into Actionable Guidance

Clinical trial protocols contain extensive scientific, operational, and regulatory requirements. Translating these requirements into consistent site-level execution can be challenging, particularly when protocols are complex or frequently amended.

A protocol twin could help bridge this gap by converting the approved protocol into structured, searchable guidance that supports day-to-day trial activities. By organizing eligibility criteria, visit schedules, procedures, endpoints, protocol references, and source data requirements, a protocol twin could help site staff quickly determine what needs to be done, when it must occur, and what documentation is required.

It could also incorporate relevant Good Clinical Practice (GCP), standard operating procedure (SOP), and regulatory requirements to support protocol-compliant execution.

Importantly, protocol twins could help identify potential operational risks before they become problems. Examples include complex eligibility assessments, narrow visit windows, amendment-related procedure changes, and requirements associated with a higher likelihood of protocol deviations.

For example, a change to an assessment schedule may affect participants differently depending on their stage in the trial. A protocol twin could help sites identify the relevant changes and determine which upcoming activities require review. This would support a clearer understanding of how an amendment applies to individual participants.

Research teams could use this guidance alongside their review of the approved protocol to support consistent execution and identify areas requiring clarification.

Patient Twins: Applying Protocol Intelligence at the Individual Patient Level

While a protocol twin provides guidance on study requirements, a patient twin applies those requirements to an individual participant's trial activities.

By bringing together protocol rules, visit schedules, and relevant patient-specific information, a patient twin could help site staff identify completed and outstanding assessments, missing documentation, and potential scheduling or compliance risks.

Consider an oncology trial with complex eligibility criteria and narrow visit windows.

A protocol twin could organize the study requirements into structured guidance, helping site staff identify critical assessments and scheduling constraints. A patient twin could then apply those requirements to an individual participant's visit schedule, flagging potential timing conflicts or missing documentation before they lead to protocol deviations.

If a participant needs to reschedule a visit, for example, the patient twin could help identify whether the proposed date affects assessment windows or related procedures. Site staff would review the information and determine whether further scheduling changes or clarification are needed. For site teams, this could support more efficient visit preparation, timely follow-up, and fewer avoidable disruptions.

For sponsors, earlier identification of operational risks could provide clinical operations teams with greater visibility into trial performance and opportunities to intervene before issues affect timelines or data quality.

These applications would complement—not replace—the clinical judgment and oversight of investigators and research staff.

From Reactive Monitoring to Proactive Risk Management

Digital twins could also help clinical research associates (CRAs) and clinical operations teams take a more proactive approach to monitoring.

By identifying patterns and emerging risks across patient visits and protocol requirements, digital twins could help monitors focus their attention where it is most needed.

For example, if a patient twin repeatedly flags potential visit-window deviations, a CRA could investigate the underlying cause. Is the issue related to patient availability, scheduling constraints, unclear protocol instructions, or site workflow?

The technology could provide an early signal, while the CRA brings the experience and site-level understanding needed to interpret the information, identify root causes, and recommend appropriate actions.

From Novotech’s perspective, earlier identification of risk should be accompanied by practical support for the site. CRAs and clinical operations teams have an important role in helping sites interpret findings, determine an appropriate response, and assess whether the underlying issue has been resolved. This is where digital tools could support closer collaboration between sites and their CRO teams.

Rather than identifying issues only after they occur, clinical operations teams could have greater opportunities to anticipate challenges, provide timely support, and prevent recurrence.

Building Trust Through Human Oversight

Realizing the potential of digital twins will require more than technological capabilities. Successful adoption will depend on data quality, practical usability, appropriate governance, and the confidence of clinical research teams.

Protocol and patient twins must operate within secure, access-controlled environments, with appropriate safeguards for patient information and clear traceability of data and decisions.

Guidance should be traceable to the applicable approved protocol and relevant participant information, with appropriate controls to manage updates. Site teams should also have a clear process for reviewing and resolving questions about the information provided.

They must also integrate effectively with existing clinical trial workflows rather than introduce additional administrative burden.

Most importantly, digital twins should serve as decision-support tools—not substitutes for experienced clinical research professionals.

Investigators must retain responsibility for clinical decisions, while CRAs and clinical operations teams provide the oversight, interpretation, and judgment necessary to ensure patient safety, protocol adherence, and data quality.

The Future of Smarter Clinical Trial Execution

As clinical trials become increasingly complex, sponsors and research sites need approaches that make protocol requirements easier to interpret, manage, and execute.

Protocol and patient digital twins offer promising opportunities to reduce administrative burden, identify operational risks earlier, and support more consistent trial execution.

However, technology alone will not solve the challenges of protocol complexity. Its value will depend on how effectively it supports the people responsible for delivering clinical trials.

For research sites, this reinforces the importance of a CRO partner that combines clinical operations expertise with an understanding of site workflows. Clear guidance on protocol requirements, timely support when questions arise, and follow-up on emerging risks remain essential, regardless of the technology used.

Novotech’s approach to site collaboration places clinical expertise and practical support at the center of that relationship. Digital twins could help strengthen this support by making relevant information more accessible and identifying issues earlier, while clinical teams continue to provide the interpretation and oversight needed for trial delivery.

Learn how working with Novotech’s clinical operations team can help your site manage complex protocol requirements and support trial delivery.

References

  1. Novotech. The Growing Role of AI at the Clinical Trial Site. Susan Johnson, June 2026.
  2. WCG. 2025 Clinical Research Site Challenges Report. 2025.
  3. U.S. Food and Drug Administration. FDA Announces Major Steps to Implement Real-Time Clinical Trials. 2026.
  4. Venkatnarayanan B. Digital Twins – A Way Forward to Unlock the Pivotal Hidden Signals to Increase ROI in Drug Discovery? DIA, April 2020.
  5. ICH. M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP).